Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways.

Cancer Drug Resist · 2020 · PMC8992570 · PMID 35582226

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The CA184-043 phase III study, testing the anti-CTLA4 ipilimumab vs placebo after RT in mCRPC patients progressing after chemotherapy with docetaxel, did not reach statistical significance for its primary endpoint of OS.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.